Abstract
Abstract
Background
Pacing-induced cardiomyopathy (PICM) is a major complication of chronic right ventricular pacing and develops in up to 25% of patients. Reliable prediction of PICM may facilitate individualized pacing strategy selection; however, currently available approaches demonstrate limited discriminative performance. This study aimed to develop and validate machine learning (ML) models for predicting PICM in patients with atrioventricular block (AVB) underlying heart failure with mildly reduced or preserved ejection fraction.
Methods
In this multicenter prospective study derived from the RISK-PICM registry (January 2002 to January 2026), 125 patients with AVB who underwent pacemaker implantation were analyzed. PICM was defined as a ≥10% reduction in left ventricular ejection fraction (LVEF) resulting in an LVEF
Results
PICM developed in 41 patients (32.8%) during a median follow-up of 4.8 years. Male sex, pre-implant minimum QTc interval, and post-implant maximum QRS duration were significantly associated with PICM in univariable Cox regression. XGBoost achieved the highest discriminative performance (AUROC 0.831; sensitivity 0.805; specificity 0.845). Feature importance analysis identified baseline LVEF and post-implant maximum QRS duration as the most influential features. Model-derived risk stratification significantly differentiated high-risk and low-risk groups on Kaplan-Meier analysis (
P
Conclusions
ML-based models, particularly XGBoost, demonstrated clinically meaningful performance for PICM and may support individualized pacing strategy selection in patients with AVB and underlying heart failure with mildly reduced or preserved ejection fraction.
Clinical Perspective
What Is New
In pacing-dependent AVB patients with HFmrEF or HFpEF, ensemble ML (XGBoost) predicted PICM with an AUROC of 0.831.
Model-derived risk stratification separated PICM-free survival (log-rank P
What Are the Clinical Implications
An ML model combining baseline LVEF, paced QRS duration, and the full parameter set may guide individualized choice between right ventricular and conduction system pacing in AVB patients with HFmrEF or HFpEF.
Using paced QRS duration combined with baseline LVEF during temporary pacing in AVB patients with HFmrEF or HFpEF, this risk estimate could inform pacing-strategy selection before permanent implantation, enabling pre-emptive use of conduction system pacing in high-risk patients.